Join us for the #IASLC 2026 Hot Topic Meeting on Resistance to Immunotherapy! 🗓️ June 25-27, 2026 📍 Dublin, Ireland 👉 ht26-iaslc.eventsair.site/full-program @iaslc.bsky.social @patrickforde.bsky.social

🫁 Most patients with #BRAF - mutant #NSCLC harbor a *non V600* alteration - a major therapeutic blind spot. Here, we review the complex biology and therapeutic challenges for non-V600 #BRAF–driven #NSCLC 📑 authors.elsevier.com/a/1mTV35Xq2Q... #BOLEROConsortium @jtoonline.bsky.social

Just out in @jtoonline.bsky.social ! First-line treatment with #BRAF/#MEK targeted therapy or with (chemo)-immunotherapy results in similar survival outcomes in #BRAF-V600 mutated #NSCLC patients. #LCSM www.jto.org/article/S155...

FDA approves a rare novel–novel oncology combination that pairs a first-in-class FAK inhibitor with a MEK–RAF glue inhibitor www.nature.com/articles/d41... Verastem’s new therapy for a form of KRAS-mutated ovarian cancer combines the kinase inhibitors defactinib and avutometinib

#BRAF V600E detection and effective BRAF/MEKi treatment in a pure epithelioid #mesothelioma upon progression on ICI (biphasic MPM at baseline). www.jtocrr.org/article/S266...

The April (and #AACR25) issue of Cancer Discovery is now online! The cover features work by Ling Cai, Nia Hammond, @faubert.bsky.social, @rjdlab.bsky.social & colleagues showing high glucose contribution to the TCA cycle is a feature of aggressive NSCLC - more here: aacrjournals.org/cancerdiscov...

Quick shout-out on these two collaborative networks (#BOLERO and #COALA) during my presentation at #ELCC25. Looking forward to advancing basic and translational research on #BRAF-mutant #NSCLC and other oncogene-driven #NSCLC. x.com/JulienMazier...

MARIPOSA final OS analysis ❇️ Significant HR 0.75 ❇️ 9% 3yr benefit ❇️ Projected mOS 4 years ❇️ Longer control of CNS disease ❗️At the cost of toxicity ❗️No data on duration of toxicity ❗️PROM and QoL data important More effective than Osimertinib Most suitable for higher risk pts #ELCC25

Three days of great science at the #EACR meeting on #persister cells. We presented our work on models of therapy-residual disease in #BRAF-mutant lung cancer. Great to have part of the #COALA and #BOLERO crowds in Lyon ! @helloeacr.bsky.social @ocalvayrac.bsky.social @maraverlab.bsky.social

Resistance to BRAFi + MEKi in #BRAF V600E melanoma patients is driven by activation of focal adhesion signaling. Avutometinib (RAF-MEK clamp) in combination with FAKi reverts resistance to BRAFi plus MEKi or to immunotherapy. dlvr.it/TJFQ3d

FAK inhibition combined with the RAF-MEK clamp avutometinib overcomes resistance to targeted and immune therapies in BRAF V600E melanoma

By transcriptomic analysis, Lubrano et al. demonstrate that FAK-regulated pathways are enriched in BRAFi+MEKi-resistant melanoma lesions. In BRAF V600E melanomas, MAPK inhibition decreases RhoE (RND3)...

dlvr.it

Impressive talk by Lise Mangiante on tissue ecology from ER+ breast cancer. #CRCL25 www.nature.com/articles/s41...

Great kick-off of the #CRCL25 symposium with a keynote lecture by Joan Massague, on metastasis initiation. www.crclsymposium2025.fr/en/program/d...